Lupin Ltd
NSE:LUPIN

Watchlist Manager
Lupin Ltd Logo
Lupin Ltd
NSE:LUPIN
Watchlist
Price: 2 177.9 INR -0.82% Market Closed
Market Cap: 994.8B INR

Relative Value

The Relative Value of one LUPIN stock under the Base Case scenario is 2 525.47 INR. Compared to the current market price of 2 177.9 INR, Lupin Ltd is Undervalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LUPIN Relative Value
Base Case
2 525.47 INR
Undervaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
12
vs Industry
29
Median 3Y
3.7
Median 5Y
3
Industry
2.7
Forward
3.7
vs History
65
vs Industry
13
Median 3Y
37.6
Median 5Y
32.5
Industry
21.6
Forward
21.9
vs History
53
vs Industry
14
Median 3Y
20.6
Median 5Y
23.7
Industry
16.9
vs History
57
vs Industry
9
Median 3Y
62.3
Median 5Y
26.2
Industry
22.9
vs History
11
vs Industry
12
Median 3Y
5.2
Median 5Y
3.7
Industry
2.3
vs History
12
vs Industry
28
Median 3Y
3.8
Median 5Y
3
Industry
3
Forward
3.8
vs History
22
vs Industry
33
Median 3Y
5.5
Median 5Y
4.8
Industry
5.6
vs History
69
vs Industry
20
Median 3Y
18.8
Median 5Y
18.1
Industry
13.4
Forward
14.6
vs History
87
vs Industry
18
Median 3Y
27.5
Median 5Y
27.4
Industry
16.7
Forward
17.8
vs History
53
vs Industry
14
Median 3Y
20.8
Median 5Y
23
Industry
16.1
vs History
42
vs Industry
12
Median 3Y
37.9
Median 5Y
32.8
Industry
18.9
vs History
12
vs Industry
16
Median 3Y
3.9
Median 5Y
2.9
Industry
2

Multiples Across Competitors

LUPIN Competitors Multiples
Lupin Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Lupin Ltd
NSE:LUPIN
994.4B INR 4 23 15.8 19.7
US
Eli Lilly and Co
NYSE:LLY
982.7B USD 16.5 53.4 35.8 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.3B USD 5.7 21 17.2 22.3
CH
Roche Holding AG
SIX:ROG
276B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
218.7B GBP 5 31.1 108.4 158.7
CH
Novartis AG
SIX:NOVN
220B CHF 4.9 19 12 15.6
US
Merck & Co Inc
NYSE:MRK
273.7B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.5 10.3
P/E Multiple
Earnings Growth PEG
IN
Lupin Ltd
NSE:LUPIN
Average P/E: 24.7
23
11%
2.1
US
Eli Lilly and Co
NYSE:LLY
53.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
21
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.1
37%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Lupin Ltd
NSE:LUPIN
Average EV/EBITDA: 401.4
15.8
9%
1.8
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Lupin Ltd
NSE:LUPIN
Average EV/EBIT: 1 714.2
19.7
10%
2
US
Eli Lilly and Co
NYSE:LLY
38.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5